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Modulating chromatin through histone methylation
orchestrates numerous cellular processes. SETD2-
dependent trimethylation of histone H3K36 is associ-
ated with active transcription. Here, we define a role
for H3K36 trimethylation in homologous recombina-
tion (HR) repair in human cells. We find that depleting
SETD2 generates a mutation signature resembling
RAD51 depletion at I-SceI-induced DNA double-
strand break (DSB) sites, with significantly increased
deletions arising through microhomology-mediated
end-joining. We establish a presynaptic role for
SETD2 methyltransferase in HR, where it facilitates
the recruitment of C-terminal binding protein inter-
acting protein (CtIP) and promotes DSB resection,
allowing Replication Protein A (RPA) and RAD51
binding to DNA damage sites. Furthermore, reducing
H3K36me3 levels by overexpressing KDM4A/
JMJD2A, an oncogene and H3K36me3/2 demethy-
lase, or an H3.3K36M transgene also reduces HR
repair events. We propose that error-free HR repair
within H3K36me3-decorated transcriptionally active
genomic regions promotes cell homeostasis. More-
over, these findings provide insights as to why onco-
genic mutations cluster within the H3K36me3 axis.INTRODUCTION
DNA double-stranded breaks (DSBs) are potentially lethal
lesions if unrepaired, and their misrepair can give rise to genome
instability, a hallmark of cancer (Jeggo and Lavin, 2009). To
maintain genome stability in response to such lesions, cells2006 Cell Reports 7, 2006–2018, June 26, 2014 ª2014 The Authorsemploy either homologous recombination (HR) or nonhomolo-
gous end-joining (NHEJ) pathways to repair DSBs. HR is initiated
by 50 end resection to generate a 30 single-stranded DNA
(ssDNA) overhang. Resection is a two-step process initiated by
removing a short oligonucleotide through the activities of the
Mre11-Rad50-Nbs1 (MRN) complex and CtIP. Extensive resec-
tion is performed by Exo1 or DNA2-BLM in conjunction with
Replication Protein A (RPA), which binds ssDNA and removes
secondary structures (Sugiyama et al., 1998; Symington and
Gautier, 2011). This, in turn, leads to RAD51 nucleofilament
formation, which promotes strand invasion of a homologous
chromatid, leading to accurate repair (Heyer et al., 2010). During
classical NHEJ (C-NHEJ), the broken ends are rapidly bound and
protected by the Ku70/Ku80 heterodimer, which acts as a plat-
form to recruit the DNA-PK catalytic subunit (DNA-PKcs).
Damaged ends are then processed and subsequently joined
by the Ligase 4 (Lig4), XRCC4, XLF complex in a template-inde-
pendent manner, which can lead to inaccurate repair (Lieber,
2010). DSBs may also be repaired through alternative end-
joining pathways, such as microhomology-mediated end-joining
(MMEJ), which do not require Ku or Lig4. Like HR, MMEJ is
initiated by resection, and end-joining is mediated through an-
nealing of short direct repeats of microhomology. MMEJ leads
to deletions and is frequently associated with chromosomal
rearrangements (McVey and Lee, 2008).
DSB repair is further facilitated through chromatin modifica-
tion by chromatin remodeling complexes, by incorporation of
histone variants, and by histone modification (Smeenk and van
Attikum, 2013). Histone H3K36 dimethylation has recently been
proposed to facilitate NHEJ, where Metnase (SETMAR) directly
mediates H3K36 dimethylation near the break site, leading to
recruitment and stabilization of NBS1 and Ku70 (Fnu et al.,
2011). Histone H3K36 is also trimethylated, which in mammalian
cells is performed uniquely by the SETD2/HYPB methyltrans-
ferase (Edmunds et al., 2008). H3K36me3 is associated with
transcriptional elongation and is found in gene coding regions,
peaking at 30 ends (Edmunds et al., 2008). SETD2-dependent
H3K36 trimethylation facilitates a number of processes within
the cell, including splicing, repression of intragenic transcripts,
and chromatin accessibility (Li et al., 2013; Wagner and Carpen-
ter, 2012). SETD2 is also mutated in a number of cancer types,
including breast, lung, acute lymphoblastic leukemia, clear cell
renal cell carcinoma, and glioma, supporting its role as a tumor
suppressor (Al Sarakbi et al., 2009; Dalgliesh et al., 2010; Fonte-
basso et al., 2013; Newbold and Mokbel, 2010; Zhang et al.,
2012). SETD2-dependent H3K36 trimethylation has recently
been shown to regulate DNA mismatch repair (Li et al., 2013).
However, SETD2-deficient cancers exhibit a wide range of
mutations, including insertions, deletions (indels), and chromo-
somal aberrations (Sato et al., 2013; Zhu et al., 2014), suggesting
an additional role for SETD2 in genome stability.
Additionally, H3K36 methylation is regulated by the KDM4/
JMJD2 family of histone demethylases. These contain JmjN-
JmjC and tandem-Tudor domains that specifically remove the
tri- and dimethyl forms of both H3K9 and H3K36, with preference
for the trimethyl form being observed in the case of KDM4A/
JMJD2A (Couture et al., 2007; Klose et al., 2006; Whetstine
et al., 2006). KDM4 family proteins are frequently overexpressed
in cancers and are associated with poor patient survival (Berry
and Janknecht, 2013; Black et al., 2013).
Here, we investigate the role of SETD2-dependent H3K36me3
in maintaining genome stability. We establish a role for
H3K36me3 in HR repair by facilitating resection. In addition,
we define a role for SETD2 and RAD51 in maintaining genome
stability through suppressing MMEJ at break sites.
RESULTS
SETD2 Suppresses Break-Induced Mutations
Tumor suppressors can suppress carcinogenesis by prevent-
ing genome instability, a hallmark of cancer. To investigate the
impact of loss of SETD2, a tumor suppressor, on genome stabil-
ity following DSB induction, we developed an I-SceI-induced
loss of function assay (HPRT+:I-SceI). Intron-encoded endonu-
clease 1 from Saccharomyces cerevisiae (I-SceI) is a rare-cutting
endonuclease that has no predicted recognition site in the
mammalian genome (Jasin, 1996). An I-SceI recognition
sequence was inserted into the endogenous HPRT exon 6 in
HT1080 (fibrosarcoma) cells. The I-SceI site maintains the
HPRT reading frame andmakes only a single amino acid change
that does not impair the function of HPRT (Figure 1A). Following
I-SceI induction, inaccurate DSB repair generates HPRT-nega-
tive mutants, which can be selected for using 6-thioguanine (6-
TG), and indels can be detected by PCR amplification using
primers flanking the break site (Figure 1A). Following small inter-
fering RNA (siRNA) knockdown and I-SceI induction, the fre-
quency of HPRT loss (mutation frequency) in SETD2-depleted
cells was 1.65%, significantly higher (p = 0.0014) than that of
nontargeting controls (1.1%). These findings resembled those
in RAD51-depleted cells in which the frequency of HPRT loss
was also significantly increased to 1.88% (p = 0.0022) compared
to nontargeting controls (Figure 1B). SETD2 and RAD51 code-
pletion (siS+SiR) also significantly increased the mutation fre-
quency to 1.52% (p = 0.037), which was similar to the frequencyCobserved following either SETD2 or RAD51 depletion (Figure 1B).
We confirmed that I-SceI protein expression and cleavage effi-
ciency were the same in cells transfected with either control
siRNA or SETD2 siRNA (Figures S1A–S1C). In addition, HPRT
gene transcription was not affected by SETD2 knockdown, as
shown by quantitative RT-PCR (qRT-PCR) of spliced and un-
spliced HPRT mRNA (Figures S1D and S1E). Therefore, the mu-
tation frequency in this system is likely to be directly associated
with misrepair of the DSB at the I-SceI site.
Further, we studied the mutation patterns across the break
site of 30 individually isolated HPRT-negative clones from each
background by PCR amplification and sequencing. HPRT-nega-
tive clones from cells treated with nontargeting control siRNA
indicated the presence of microdeletions of 2–5 bp, consistent
with DSB repair by C-NHEJ. Larger microdeletions were also
observed that were associated with regions of microhomology
located either side of the break site, consistent with DSB repair
through MMEJ (Figures 1C and S1F).
Sequence analysis indicated that SETD2-depleted cells ex-
hibited a significant increase in average deletion length (11 bp,
p < 0.0001) compared to control cells (5 bp) (Figures 1C and
1D). RAD51-depleted cells exhibited a further significant in-
crease in the average deletion length (22 bp, p = 0.014) (Figures
1C and 1D). RAD51 and SETD2 codepletion generated deletion
lengths (an average of 8 bp) comparable to those observed
following SETD2 knockdown, which in turn was significantly
higher than the nontargeting control (p = 0.026) (Figures 1C
and 1D). Insertions at the HPRT break site were also detected.
However, the frequency and size of the insertions was not signif-
icantly altered between SETD2-depleted cells, SETD2/RAD51
codepleted and nontargeting controls.
We next examined the mechanism for misrepair in cells exhib-
iting deletions. We found that the frequency of microhomology-
mediated end-joining (MMEJ) was significantly increased in
SETD2 and RAD51-depleted cells (p < 0.05) (Figures 1E and
S1G). This suggested that HR-deficient cells use MMEJ as an
alternative repair mechanism, which gives rise to a mutation
signature of sequence loss between regions of microhomology.
These results support a role for SETD2 in tumor suppression by
maintaining genome stability through preventing deleterious
mutations arising in response to DSBs. These findings further
identify a similar break-induced mutation signature between
SETD2- and RAD51-depleted cells, suggesting an early role for
SETD2 in HR repair.
SETD2 Is Required for Homologous Recombination
Repair
To test the role for SETD2 in DSB repair, we depleted SETD2 in
U2OS and HeLa cells using two independent siRNAs and
measured the clonogenic survival following exposure to DNA-
damaging agents. SETD2 knockdown significantly reduced sur-
vival after treatment with mitomycin C (MMC), camptothecin
(CPT), or ionizing radiation (IR) in U2OS cells and HeLa cells
compared to nontargeting controls (Figures 2A and S2A). These
results identify a role for SETD2 in the cellular response to DNA
damage and are consistent with a role for SETD2 in DSB repair.
SETD2 knockdown was validated by western blotting (Fig-
ure 2B). Western blotting also showed that SETD2 knockdownell Reports 7, 2006–2018, June 26, 2014 ª2014 The Authors 2007
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Figure 1. SETD2- and RAD51-Depleted Cells Exhibit a Common Break-Induced Mutation Signature
(A) Schematic map of the HPRT+:I-SceI assay, where arrows indicate PCR primers used to amplify genomic DNA to allow sequencing across the break site (see
Supplemental Experimental Procedures).
(B) Mutation frequency of nontargeting control (NT), SETD2-depleted, RAD51-depleted, and SETD2/RAD51-codepleted cells (siS+siR) after I-SceI induced DSB.
Error bars represent SEM and *p < 0.05; n.s., not significant.
(legend continued on next page)
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significantly reduced global levels of H3K36me3, confirming
SETD2 as the major H3K36me3 methyltransferase in human
cells (Figure 2B). Because RAD51 is more likely to be affected
among DNA repair genes by siRNA off-target effects (Adamson
et al., 2012), we also confirmed that SETD2 knockdown by
siRNA did not affect the RAD51 protein levels (Figure 2B).
We confirmed that SETD2 knockdown had no effect on the
expression of major HR proteins, including BRCA2, RAD50,
CtIP, MRE11, and RPA and the NHEJ protein KU80 (Figure S2B).
We also observed no changes to the cell cycle after SETD2
knockdown (Figure S2C).
Both MMC and CPT induce S phase-specific DSBs, which are
predominantly repaired by HR (Arnaudeau et al., 2001; Moyna-
han et al., 2001). To test a possible role for SETD2 in HR repair,
we used a well-characterized GFP-based reporter for HR (DR-
GFP). The HR reporter contains an I-SceI recognition sequence,
which upon I-SceI expression is cleaved to generate a DSB. DSB
repair by HR using a direct repeat within the reporter cassette
as a template results in an intact GFP gene (Figure 2C)(Pierce
et al., 1999). SETD2 knockdown by two independent siRNAs
significantly reduced HR repair of an I-SceI induced DSB by
67%–77% compared to nontargeting control cells (p < 0.0003)
(Figure 2D). As a control for the HR reporter, knockdown of
RAD51 reduced HR activity by 97% (p < 0.0001), whereas
DNA-PKcs inhibitor NU7441 had no effect on HR (Figure 2D).
In contrast, SETD2 knockdown had no effect on repair of an I-
SceI induced DSB in an NHEJ reporter (IRES-TK-EGFP) in which
joining of two I-SceI sites separated by a thymidine kinase gene
(TK) results in GFP expression (Figures 2E and 2F)(Ogiwara et al.,
2011). As a control, RAD51 had no effect on the same NHEJ re-
porter, whereas the DNA-PK inhibitor NU7441 reduced NHEJ
activity by 98% (p < 0.0001) (Figure 2F). These results identify
a role for SETD2 in HR repair.
An Early Role for SETD2 in Homologous Recombination
To further investigate the role of SETD2 in DSB repair, we exam-
ined the rate of repair following IR. We used gH2AX foci as a
marker of DNA damage and found that following exposure to
5 Gy IR, SETD2 knockdown significantly delayed removal of
gH2AX foci at 48 hr (p < 0.003) compared to nontargeting con-
trols, supporting a role for SETD2 in efficient DSB repair (Fig-
ure 3A). We next investigated the effect of SETD2 depletion on
the recruitment of HR repair proteins following DNA damage.
SETD2 knockdown resulted in significantly reduced RAD51
foci formation 4 and 8 hr after exposure to IR compared to non-
targeting controls (p < 0.0013) (Figure 3B). SETD2 knockdown
also significantly reduced RAD51 foci formation after exposure
to CPT (p < 0.05) (Figure S2D).
We also examined the effect of SETD2 depletion on RPA
recruitment, where we induced DSBs in S phase cells using
CPT or MMC. A significant reduction in RPA foci formation was(C) Representative sequence alignments of the above-mentioned PCR products
RAD51-codepleted backgrounds, respectively.
(D) Average length of deletions (bp) in different backgrounds, where each dot rep
***p < 0.001.
(E) Frequency of repair by MMEJ in deletion mutants isolated from different bac
portions,’’ *p < 0.05. See also Figure S1.
Cobserved after CPT or MMC treatment following SETD2 knock-
down compared to nontargeting controls (p < 0.023) (Figures
3C and S2E). SETD2 knockdown leads to reduced H3K36me3
in the nuclei as confirmed by costaining the cells with antibodies
against H3K36me3 and RPA (Figure S2F). Together, these find-
ings support a role for SETD2 in promoting HR through facili-
tating recruitment of RPA and RAD51 to DNA damage sites.
To further confirm the impact of SETD2 loss on the recruitment
of HR factors to the site of DSBs, we performed chromatin immu-
noprecipitation (ChIP) near the I-SceI site in the DR-GFP
cassette (Figure S3A). The I-SceI site is located within the
DR-GFP cassette under the control of the highly active CMV
promoter, and thus H3K36me3, which is associated with active
transcription, is predicted to be present throughout the cassette.
After induction of DSBs by I-SceI, no change in H3K36me3
or SETD2 levels was detected proximal or distal to the break
site after 8, 24, or 48 hr following I-SceI transfection (Fig-
ure S3B). The results were also quantified by ChIP-qPCR (Fig-
ure S3C). Although other groups also observed no changes to
H3K36me3 level after DSB, globally (Fnu et al., 2011) or locally
at the break site (Pei et al., 2011; Aymard et al., 2014), we were
surprised by the lack of reduction in H3K36me3 or SETD2
knowing that regional transcriptional silencing has been
observed at sites of DSBs (Shanbhag et al., 2010). We speculate
that the unexpected maintenance of H3K36me3 at the DSB site
by SETD2 may serve as an anchor to mediate HR repair.
We monitored recruitment of major HR factors to the DSB
site in the ChIP system. RPA and RAD51 were recruited to the
DSB site, resulting in increased binding to the ‘‘up’’ site 18 hr
after I-SceI transfection, compared to uncut controls (Fig-
ure 3D). SETD2 depletion substantially reduced the recruitment
of RPA andRAD51 after the I-SceI cut (Figure 3D). SETD2 protein
depletion was validated by western blotting (Figure S3D), and
was further confirmed by the absence of SETD2 or H3K36me3
at the break site (Figure 3D). These findings are consistent with
the RPA and RAD51 foci data, indicating that SETD2 is required
to recruit RPA and RAD51 to DSB sites. Together, these find-
ings confirm a presynaptic role for SETD2 in facilitating HR repair
of DSBs.
H3K36me3 Is Required for Homologous Recombination
Repair
To investigate if the methyltransferase activity of SETD2 is
required for its role in HR, we generated two doxycycline-induc-
ible U2OS cell lines, where either a wild-type SETD2 cDNA or a
methyltransferase-dead SETD2 cDNA was inserted behind a
Tet operator in the genomeof U2OS cells. Upon addition of doxy-
cycline to the cell culture medium, the Tet operator was dere-
pressed and the wild-type or mutant SETD2 was expressed.
Both cDNA constructs were mutated so that they are refractory
to SETD2 siRNA#3. The methyltransferase-dead SETD2 wasin nontargeting control (NT), SETD2-depleted, RAD51-depleted, and SETD2/
resents an independent clone. The lines represent mean and SEM, *p < 0.05,
kgrounds. p values calculated by statistical analysis ‘‘difference between pro-
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Figure 2. SETD2 Is Required for Homologous Recombination
(A) Clonogenic survival of SETD2 knockdown (si#3 and si#5) or nontargeting control (NT) U2OS cells treated with indicated concentrations of MMC, CPT, and IR.
Error bars show SEM from three independent experiments.
(B) Western blots showing levels of SETD2, RAD51, and H3K36me3 72 hr after siRNA transfection.
(C) Schematic map of the DR-GFP cassette for assessing HR efficacy.
(D) HR repair efficacy of reporter cells treated with nontargeting control siRNA (NT), SETD2 siRNAs (si#3 and si#5), RAD51 siRNA (siRad51), or DNA-PK inhibitor
NU7441 (Axon), indicated by the percentage of GFP-positive cells. Error bars show SEM from three independent experiments. ***p < 0.001.
(E) Schematic map of the NHEJ cassette.
(F) NHEJ repair efficacy of reporter cells treated with nontargeting control siRNA (NT), SETD2 siRNAs (si#3 and si#5), RAD51 siRNA (siRAD51), or DNA-PK in-
hibitor NU7441, indicated by the percentage of GFP-positive cells. Error bars show SEM from three independent experiments. ***p < 0.001. See also Figure S2.
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Figure 3. SETD2 Is Required for the Recruitment of RPA and RAD51
(A and B) gH2AX (A) or RAD51 (B) foci formation at indicated times after IR (5 Gy) in U2OS cells treatedwith nontargeting control siRNA (NT) or SETD2 siRNAs (si#3
and si#5). Error bars represent SEM from three independent experiments.
(C) RPA32 foci formation at indicated times after treatment with CPT (10 mM) in U2OS cells transfected with control siRNA (NT) or SETD2 siRNAs (si#3 and si#5).
Representative fluorescent images are shown; scale bar, 20 mm. For each condition, 45 fields and at least 500 cells were examined by Incell (GE Healthcare). Error
bars show SEM from three independent experiments. ***p < 0.001, **p < 0.01, *p < 0.05.
(D) ChIP analysis on DR-GFP U2OS cells transfected with nontargeting control (NT) or SETD2 siRNA for 72 hr, followed by transfection of either vector or I-SceI
plasmid for a further 18 hr, as indicated. ChIP on the ‘‘up’’ DNA site of the DR-GFP cassette was performed on the lysate using antibodies against nonspecific Ig
(NS), H3K36me3 (Abcam), SETD2 (Abcam), RAD51 (Santa Cruz Biotechnology), or RPA (Millipore); inputs (IN) are also indicated.
See also Figures S2 and S3.mutated at two amino acid residues located within the catalytic
site of the SET domain, which are conserved with yeast Set2.
The corresponding mutations in yeast were shown to abolishCthe methyltransferase activity (Rea et al., 2000;Strahl et al.,
2002) (Figure 4A). Both arginine (R) and cysteine (C) residues
were mutated in the methyltransferase-dead (MD) cDNA byell Reports 7, 2006–2018, June 26, 2014 ª2014 The Authors 2011
Figure 4. H3K36me3 Is Required for Efficient HR Repair
(A) Schematic map showing site-directed mutagenesis for abolishing the methyltransferase activity of SETD2, with both R and C residues mutated simulta-
neously. Sequence alignment of human SETD2 and Saccharomyces cerevisiae Set2 and Schizosacchromyces pombe Set2 amino acid sequences reveals
evolutionarily conserved residues that reside in the SET domain.
(B) RPA32 foci formation at 2 hr after treatment with CPT (10 mM) in cells transfected with SETD2 siRNA. WT: T-REx U2OS clone (see Experimental Procedures)
withwild-typeSETD2 cDNA integrated but not expressing exogenous SETD2.WT+DOX: the sameWT clone expressing exogenouswild-type SETD2.MD: T-REx
U2OS clone with methyltransferase-dead mutant SETD2 cDNA integrated but not expressing exogenous SETD2. MD+DOX: the same MD clone expressing
exogenous mutant SETD2. Error bars show SEM from three independent experiments, *p < 0.05.
(legend continued on next page)
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site-directed mutagenesis (see Supplemental Experimental Pro-
cedures). Western blot analysis confirmed that doxycycline-
induced expression of wild-type SETD2 could restore the level
of H3K36me3 after siSETD2 treatment, whereas expression of
methyltransferase-dead SETD2 could not restore the level of
H3K36me3 (Figure S4A).
We depleted endogenous SETD2 with siRNA#3 and examined
the rescue of the phenotype by the two constructs. Although the
wild-type construct increased foci formation of RPA and RAD51
after DNA damage in siSETD2 cells, the methyltransferase-dead
mutant did not (Figures 4B and 4C). This is consistent with the
observation that the wild-type construct partially restored HR ef-
ficiency whereas the methyltransferase-dead (MD) mutant did
not (Figure 4D). Five to six clones containing each construct
were independently isolated and tested. All WT clones were
able to restore HR efficiency, but none of the MD clones showed
rescue (Figures S4B and S4C).
The observation that the methyltransferase-dead SETD2
mutant could not rescue HR efficiency suggested that
H3K36me3 is required for efficient HR. To test this further, we
used SETD2-independent approaches to disrupt H3K36me3
levels. First, we overexpressed KDM4A, an oncogene and a de-
methylase specific for tri- and dimethylated histone H3K36 and
H3K9, predicting that overexpression of KDM4A would reduce
the level of H3K36me3 and thus impair HR. Therefore, a doxycy-
cline-inducible KDM4A-expression U2OS cell line was gener-
ated. Upon addition of doxycycline, KDM4Awas overexpressed,
which led to a global reduction in H3K36me3 levels (Figure 4E).
We then compared the recruitment of the HR factors in this
cell line with or without KDM4A overexpression. We found
that KDM4A overexpression inhibited the formation of RPA and
RAD51 foci after DNA damage (Figures 4F and 4G). Accordingly,
KDM4A overexpression also reduced HR efficiency as assessed
by the HR reporter (p = 0.0078) (Figure 4H). Using the same cell
line without KDM4A cDNA integration, we found that doxycy-
cline itself had no effect on HR efficiency of U2OS cells (Fig-
ure S4D). These findings indicate that overexpression of the
oncogene KDM4A significantly reduces levels of H3K36me3
and HR.
Second, we utilized a dominant-negative mutation in the his-
tone H3.3 gene (H3.3K36M) that was recently shown to reduce(C) RAD51 foci formation at 4 hr after IR (5 Gy) in cells transfected with SETD2 si
independent experiments, **p < 0.01.
(D) HR efficacy in cells transfected with NT or SETD2 siRNA. The clones used are
***p < 0.001.
(E) Western blot showing levels of KDM4A, H3K36me3 and H3 following KDM4A
cells (see Experimental Procedures).
(F) RPA32 foci formation at indicated time after 2 hr CPT (10 mM) treatment in KD
show SEM from three independent experiments, *p < 0.05.
(G) RAD51 foci formation 8 hr after IR (5 Gy) in KDM4A T-REx cells treated w
independent experiments. *p < 0.05.
(H) HR repair efficacy in KDM4A T-REx DR-GFP U2OS cells treated with or wit
experiments. **p < 0.01.
(I) Western blot showing levels of H3K36me3 and H3 in U2OS cells with stably
Experimental Procedures).
(J) RPA32 foci formation at indicated time after 2 hr CPT (10 mM) treatment in
independent experiments.
(K) RAD51 foci formation 8 hr after IR (5 Gy) in H3.3 or H3.3K36M stable expressio
also Figure S4.
CH3K36me3 specifically without affecting other histone methyl-
ations (Lewis et al., 2013). Accordingly, in cells expressing
the mutant H3.3K36M transgene, global levels of H3K36me3
were depleted compared to the wild-type H3.3 control (Fig-
ure 4I). Cells expressing H3.3K36M also exhibited delayed
RPA and RAD51 foci formation following DNA damage (Figures
4J and 4K), consistent with similar delays seen in KDM4A over-
expressing cells or SETD2-depleted cells. Neither KDM4A
overexpression nor H3.3K36M expression affected cell cycle
progression as assessed by BrdU incorporation (Figures
S4E and S4F), thus excluding the possibility that the reduc-
tion in RPA, RAD51 foci formation and HR efficacy was due
to cell cycle effects. The common feature of all three
different systems (SETD2 knockdown and rescue, KDM4A
overexpression, and H3.3K36M expression) was the reduction
in the recruitment of HR proteins and HR efficiency associated
with reduced H3K36me3. Together these findings confirm a
role for H3K36me3 in HR.
SETD2 Promotes DSB End Resection
Lens epithelium-derived growth factor p75 (LEDGF) binds to
H3K36me3 constitutively through its PWWP domain. Upon
DNA damage LEDGF recruits CtIP, which facilitates the resec-
tion step during HR repair (Daugaard et al., 2012). Accordingly,
we were able to coprecipitate LEDGF and H3K36me3, indepen-
dently of DNA damage in U2OS cells (Figure 5A). LEDGF binding
to chromatin was reduced upon SETD2 depletion, consistent
with preferential binding of LEDGF to H3K36me3 (Eidahl et al.,
2013), and was DSB independent (Figure 5B). We predicted
that the reduced LEDGF binding following SETD2 depletion
would reduce recruitment of CtIP upon damage. We therefore
used micro-irradiation to induce localized DSBs and studied
the recruitment of CtIP using a U2OS cell line expressing GFP-
tagged CtIP (Sartori et al., 2007). We found CtIP to be localized
to sites of DNA damage marked by gH2AX (Figure 5C). In
contrast, SETD2 knockdown resulted in reduced recruitment of
CtIP to the DNA damage site as marked by gH2AX (Figure 5C).
If SETD2 facilitates HR through LEDGF binding and CtIP recruit-
ment, we would expect SETD2 to be epistatic with CtIP. Indeed,
codepletion of SETD2 and CtIP (siC+siS) showed the same level
of reduction in HR as CtIP-depletion alone (Figures 5D and S5A).RNA. The clones used are the same as in (B). Error bars show SEM from three
the same as in (B); error bars show SEM from three independent experiments,
induction with 5 mg/ml doxycycline (DOX) for 72 hr in the KDM4A T-REx U2OS
M4A T-REx cells treated with or without 5 mg/ml doxycycline (DOX). Error bars
ith or without 5 mg/ml doxycycline (DOX). Error bars show SEM from three
hout 5 mg/ml doxycycline (DOX). Error bars show SEM for three independent
integrated H3.3 (control) or H3.3K36M lentiviral construct (see Supplemental
H3.3 or H3.3K36M stable expression cells. Error bars show SEM from three
n cells. Error bars show SEM for three independent experiments, *p < 0.05. See
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Figure 5. SETD2 Promotes HR through LEDGF/CtIP-Facilitated Resection
(A) Coimmunoprecipitation of LEDGF and H3K36me3 in the presence or absence of DNA damage. U2OS cells were left untreated (U) or treated with CPT (15 mM
for 4 hr). Reciprocal co-IPs are shown.
(B) ChIP analysis of LEDGF binding to the DSB site before and after I-SceI induction in NT or SETD2 knockdown DR-GFP cells. siNT, control siRNA-treated cells
before cut; siS, SETD2 siRNA-treated cells before cut; siNT+IScI, control siRNA-treated cells after cut; siS+IScI: SETD2 siRNA-treated cells after cut. Numbers
were quantified from one ChIP-PCR experiment and show LEDGF-ChIP over input.
(C) Microirradiation showing CtIP recruitment to the damage site in U2OS cells treated with nontargeting control siRNA (NT) or SETD2 siRNAs (si#3 and si#5).
Fluorescent images were acquired using a confocal microscope (Zeiss); scale bars, 20 mm.
(D) HR efficacy (as measured by GFP reporter assay as in Figure 2D) in cells transfected with control siRNA (NT) or CtIP siRNA (siCtIP) or both CtIP and SETD2
siRNA (siC+siS). Error bars show SEM from three independent experiments, **p < 0.01, n.s. not significant.
(E) CtIP depletion impedes resection at an AsiSI induced DSB. DNA was extracted from 4OHT-treated or untreated DIvA cells, transfected with control or CtIP
siRNA, as indicated. Resection was analyzed, using a protocol detailed in Zhou et al. (2014), at an AsiSI-induced DSB reported to be repaired by a RAD51-
dependent pathway (DSB-II in Aymard et al., 2014). The mean and SEM (n = 4, technical replicate) of a representative experiment are presented.
(F) SETD2 depletion impedes resection at an AsiSI induced DSB. DNA was extracted from 4OHT-treated or untreated DIvA cells, transfected with control or
SETD2 siRNA, as indicated. Same as in (E) except that cells were transfected with a siRNA directed against SETD2. Themean and SEM (n = 4, technical replicate)
of a representative experiment are presented. See also Figure S5.These findings are consistent with the hypothesis that SETD2-
dependent H3K36me3 promotes recruitment of CtIP by LEDGF
to break sites.2014 Cell Reports 7, 2006–2018, June 26, 2014 ª2014 The AuthorsReduced CtIP recruitment, together with the reduced RPA foci
formation following SETD2 depletion, suggested that SETD2-
dependent H3K36 trimethylation might promote DSB resection.
AB
Figure 6. Model for the Role of SETD2-
Dependent H3K36me3 in HR and Genome
Stability
(A) SETD2-dependent H3K36 trimethylation
constitutively recruits LEDGF to chromatin.
Following DNA double-strand break, LEDGF re-
cruits CtIP, thereby promoting resection, facili-
tating RPA and RAD51 recruitment.
(B) In the absence of H3K36 trimethylation, lack of
LEDGF chromatin association results in reduced
recruitment of CtIP after double-strand breaks,
impairing resection and HR, leading to elevated
levels of MMEJ and genome instability.To directly measure resection, we used an in vivo resection
assay (Zhou et al., 2014) in which levels of ssDNAwere assessed
at increasing distances from a specific DSB induced by the AsiSI
restriction enzyme, which was found to recruit RAD51 (Iacovoni
et al., 2010; Aymard et al., 2014). Following DSB induction
(+4OHT), ssDNA was readily detected 231 bp from the AsiSI
break site (DSB-II in Aymard et al., 2014) and at reduced levels
further from the break site. Following CtIP depletion, ssDNA
levels were significantly reduced at 231 bp (p = 2.2 3 105)
and 918 bp (p = 0.057) from the break site compared to control
siRNAs (Figure 5E). Following SETD2 depletion, ssDNA levels
were also significantly reduced at 231 bp (p = 0.021) and
918 bp (p = 0.037) from the break site compared to control
siRNAs (Figure 5F), and SETD2 depletion did not affect DSB
induction at this site as assayed by XRCC4 ChIP (Figure S5B),
thus confirming a role for SETD2 in facilitating DSB resection.
DISCUSSION
The SETD2 gene encoding the H3K36 trimethyltransferase is
among the most mutated in human cancers (Lawrence et al.,
2014). Yet, how SETD2 functions to suppress the genome
instability frequently observed in SETD2-deficient cancer cells
is unknown (Sato et al., 2013; Zhu et al., 2014). Here, we
describe a role for SETD2-dependent H3K36 trimethylation in
facilitating error-free DSB repair and genome stability through
efficient HR. Our data support a model in which LEDGF is
constitutively anchored to H3K36me3-decorated chromatin
through its PWWP domain. Upon DNA damage, chromatin-
bound LEDGF recruits CtIP, which promotes resection—an
essential step in HR repair (Figure 6A). In the absence of
SETD2-dependent H3K36me3, the chromatin association of
LEDGF is compromised, and DNA damage-induced CtIP
recruitment is impaired, leading to reduced resection and HR
and an increase in error-prone MMEJ and subsequent genome
instability (Figure 6B). Our data do not, however, excludeCell Reports 7, 2006–201the possibility that other H3K36me3
binding factors may also contribute to
efficient HR.
The involvement of H3K36me3 in HR
raises the question as to whether this his-
tone mark is DSB inducible or preset to
determine the choice of repair pathways.We did not detect any appreciable increase in H3K36me3 levels
at the break site following I-SceI induction. These findings are
consistent with previous observations indicating that
H3K36me3 levels do not change following DNA damage, either
globally (Fnu et al., 2011) or locally (Aymard et al., 2014; Pei
et al., 2011). Given that SETD2-dependent H3K36 trimethylation
strongly correlates with actively transcribed regions of the
genome (Edmunds et al., 2008; Yoh et al., 2008), our findings
thus support a spatial link between HR and transcriptionally
active, H3K36me3 decorated regions of the genome. Indeed,
because HR repair is usually error free, this would be expected
to protect genome integrity following DSB induction or replica-
tion fork collapse at such sites, which would be important in
maintaining cell homeostasis.
Genome-wide sequencing has suggested certain mutation
signatures are associated with specific cancer types (Alexan-
drov et al., 2013) but lacks the power to identify driver mutations
that give rise to thatmutation signature. Here, we use a system to
determine the impact of individual gene dysfunction on mutation
patterns arising during the repair of a single DSB. We show that,
by depleting SETD2 or RAD51 HR proteins, DSB induction leads
to significantly increased mutation frequencies associated with
deletions within six cell cycles (5 days). These findings identify
a role for SETD2, like RAD51, in suppressing break-induced
mutations. Further mechanistic analysis indicated that deletions
arising from SETD2 or RAD51 depletion resulted from a signifi-
cant increase in error-prone MMEJ. We propose that MMEJ
arises from failed HR. SETD2 loss results in partial resection,
short ssDNA 30 ends and reduced RPA foci. These partially re-
sected ends are insufficient to promote efficient HR and are no
longer substrates for C-NHEJ. Instead, these partially resected
ends become substrates for MMEJ. Similarly, following RAD51
depletion, whereas resection proceeds normally, HR is blocked
presynaptically, resulting in the accumulation of longer unre-
paired resected ends. Such ends are no longer substrates for
C-NHEJ, and, because HR cannot proceed, the ends are instead8, June 26, 2014 ª2014 The Authors 2015
rejoined by MMEJ. Extensive resection following RAD51 loss
facilitates annealing between regions of microhomology further
from the break site, thus leading to larger deletions than those
observed for SETD2. The observations that HR was significantly
reduced whereas C-NHEJ was unchanged following SETD2
or RAD51 depletion are consistent with this model. Together,
these findings suggest a role for HR in maintaining genome sta-
bility through suppression of MMEJ. This ‘‘real-time’’ mutation
study can therefore provide important insights into how loss of
these genes contributes to somatic mutation and intratumor
heterogeneity, and it highlights the importance of HR repair
genes in maintaining genome stability.
SETD2 is a tumor suppressor and its loss is an important step
in the progression of a number of cancer types (Dalgliesh et al.,
2010; Fontebasso et al., 2013; Gerlinger et al., 2012). Our find-
ings provide mechanistic insights into how SETD2 functions
as a tumor suppressor. Moreover, all three Tudor domain-
containing KDM4/JMJD2 proteins (A, B, and C) are frequently
overexpressed in various cancers, including breast, colorectal,
lung, and prostate (Berry and Janknecht, 2013). Our findings
predict that overexpression of these KDM4 family members
causes genome instability and tumorigenesis through loss of
H3K36me3-mediated HR repair. The identification of a role for
H3K36me3 in facilitating HR repair, in addition to its recently
described role in mismatch repair (Li et al., 2013), establishes
the H3K36me3 chromatin mark as an important functional
node for maintaining genome stability.
EXPERIMENTAL PROCEDURES
I-SceI-Inducible HPRT Mutation Assay
The reporter HT1080 cell line with a functional but I-SceI-cleavable HPRT
gene was generated by inserting an 18 bp I-SceI recognition site into exon 6
of the HPRT gene using gene targeting. Reporter cells were transfected with
the I-SceI plasmid 48 hr after siRNA knockdowns. The cells were allowed to
repair in a nonselective medium for 5 days before seeding and selecting for
HPRT-negative cells using 6-TG (15 mg/ml).
Themutation frequencywascalculated as the number ofHPRT-negative col-
onies divided by number of cells plated, after correcting for plating efficiency.
To determine the mutation sequence, individual single-cell colonies were iso-
lated, and genomic DNA spanning the DSB junction was PCR-amplified using
the primers flanking the I-SceI site. Sequence alignment of the PCR products
was conducted using the DNA Data Bank of Japan (DDBJ) ClustalW program.
In Vivo DNA End Resection Assay
DIvA cells (DSB Inducible via AsiSI [Aymard et al., 2014]) were transfected with
siRNA using the Cell Line Nucleofactor kit V (Amaxa) according to the manu-
facturer’s instructions. Forty-eight hours after siRNA transfection, cells were
treated or not with 300 nM of 4-hydroxytamoxifen (4OHT) (Sigma; H7904) for
4 hr. DNAwas purified using QIAGENDNeasy kit. Single-stranded DNA gener-
ated at an AsiSI-induced DSB was analyzed using the procedure described
in Zhou et al. (2014), with the modifications described in Supplemental
Experimental Procedures. The percentage of ssDNA was calculated with the
following equation: ssDNA%= 1/(2(DCt1) + 0.5)3100, where DCt is calculated
by subtracting the Ct obtained from mock-digested sample from the BanI-
digested sample.
Generation of Inducible KDM4A Overexpression Cell Lines
U2OS-Flp-In/T-REx cells express the Tet repressor and contain a single Flp-In
site (Gordon et al., 2009). U2OS-Flp-In/T-REx/DRGFP cells were generated by
integrating the pDR-GFP expression plasmid (Pierce et al., 1999) into the
U2OS-Flp-In/T-REx cells. The KDM4A cDNA (Genecopoeia) was cloned into2016 Cell Reports 7, 2006–2018, June 26, 2014 ª2014 The Authorsthe pDESTfrtto destination vector by a Gateway LR reaction (Life Technolo-
gies). U2OS-Flp-In/T-REx or U2OS-Flp-In/T-REx/DRGFP cells were cotrans-
fected with the resulting KDM4A destination plasmid and pOG44 (Invitrogen).
Stable clones that express the KDM4A protein under the control of the T-REx
system were subjected to the treatments indicated.
Data Analysis
Data points from individual assays represent mean ± SEM. Statistical signifi-
cance between two conditions was assessed by a two-tailed unpaired t test.
*p < 0.05, **p < 0.01, ***p < 0.001, and n.s. represents pR 0.05.
Full details of all other experimental procedures are given in the Supple-
mental Experimental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2014.05.026.
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